Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study

Thomas Yau, Ahmed Kaseb, Ann-Lii Cheng, Shukui Qin, Andrew X Zhu, Stephen L Chan, Tamar Melkadze, Wattana Sukeepaisarnjaroen, Valery Breder, Gontran Verset, Edward Gane, Ivan Borbath, Jose David Gomez Rangel, Baek-Yeol Ryoo, Tamta Makharadze, Philippe Merle, Fawzi Benzaghou, Steven Milwee, Zhong Wang, Dominic Curran, Robin Kate Kelley, Lorenza Rimassa

Open source

DOI: 10.1016/s2468-1253(23)00454-5
Published: 2024-04
Container: The Lancet Gastroenterology & Hepatology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2468-1253-23-00454-5,
  title = {Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study},
  author = {Thomas Yau and Ahmed Kaseb and Ann-Lii Cheng and Shukui Qin and Andrew X Zhu and Stephen L Chan and Tamar Melkadze and Wattana Sukeepaisarnjaroen and Valery Breder and Gontran Verset and Edward Gane and Ivan Borbath and Jose David Gomez Rangel and Baek-Yeol Ryoo and Tamta Makharadze and Philippe Merle and Fawzi Benzaghou and Steven Milwee and Zhong Wang and Dominic Curran and Robin Kate Kelley and Lorenza Rimassa},
  year = {2024},
  journal = {The Lancet Gastroenterology \&amp; Hepatology},
  doi = {10.1016/s2468-1253(23)00454-5},
  url = {https://doi.org/10.1016/s2468-1253(23)00454-5}
}

RIS

TY  - JOUR
TI  - Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
AU  - Thomas Yau
AU  - Ahmed Kaseb
AU  - Ann-Lii Cheng
AU  - Shukui Qin
AU  - Andrew X Zhu
AU  - Stephen L Chan
AU  - Tamar Melkadze
AU  - Wattana Sukeepaisarnjaroen
AU  - Valery Breder
AU  - Gontran Verset
AU  - Edward Gane
AU  - Ivan Borbath
AU  - Jose David Gomez Rangel
AU  - Baek-Yeol Ryoo
AU  - Tamta Makharadze
AU  - Philippe Merle
AU  - Fawzi Benzaghou
AU  - Steven Milwee
AU  - Zhong Wang
AU  - Dominic Curran
AU  - Robin Kate Kelley
AU  - Lorenza Rimassa
PY  - 2024
JO  - The Lancet Gastroenterology &amp; Hepatology
DO  - 10.1016/s2468-1253(23)00454-5
UR  - https://doi.org/10.1016/s2468-1253(23)00454-5
ER  -

APA

Yau, T., Kaseb, A., Cheng, A., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., Verset, G., Gane, E., Borbath, I., Rangel, J. D. G., Ryoo, B., Makharadze, T., Merle, P., Benzaghou, F., Milwee, S., Wang, Z., Curran, D., Kelley, R. K., & Rimassa, L. (2024). Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(23)00454-5

Source records

crossref · retrieved 2026-09-27T06:11:42.764Z